Symbiotec Pharmalab Q2 FY27 Results: Revenue ₹2200 Cr, Profit ₹485 Cr
Symbiotec Pharmalab reported Q2 FY27 results with standalone revenue at ₹2,402 crore and profit before tax at ₹652 crore. Consolidated revenue was ₹2,800 crore, with profit before tax at ₹640 crore. The company also completed its IPO, raising ₹1,420 crore, which was utilized for debt repayment and general corporate purposes.
The announcement contains unaudited financial results for both standalone and consolidated operations, which are material information for investors. The details of the IPO and its utilization are also significant.
The company reported strong financial results with significant revenue and profit figures for the quarter and half-year. The successful completion and utilization of IPO proceeds also contribute positively.
Symbiotec Pharmalab Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a total income of ₹2,402.48 crore for the standalone operations in the quarter, with expenses amounting to ₹1,750.39 crore, leading to a profit before tax of ₹652.09 crore. For the consolidated operations, total income was ₹2,800.40 crore and total expenses were ₹2,159.96 crore, resulting in a profit before tax of ₹640.44 crore.
For the half-year ended September 30, 2026, standalone total income stood at ₹4,706.38 crore, with expenses of ₹3,424.09 crore, and a profit before tax of ₹1,282.29 crore. Consolidated total income for the half-year was ₹4,985.28 crore, with expenses of ₹4,169.52 crore, and a profit before tax of ₹815.76 crore.
The company also provided details on its Initial Public Offering (IPO) which was completed during the quarter ended September 30, 2026. The IPO involved the issuance of 1,77,86,442 equity shares at ₹988 per share, with net proceeds of ₹1,420.25 crore. These proceeds were utilized for prepayment of borrowings and general corporate purposes.
The Board of Directors meeting, where these results were approved, commenced at 04:30 p.m. and concluded at 5:30 p.m. on November 5, 2026. The trading window for dealing in the company's securities will remain closed until 48 hours from the announcement.
What to do with a filing like this
Symbiotec Pharmalab Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Symbiotec Pharmalab Limited. Read the original for the full detail.